-
公开(公告)号：US20240285649A1
公开(公告)日：2024-08-29
申请号：US17923539
申请日：2021-05-06
发明人： Xin Du , Tao Tom Du , Weiwei Hua
摘要： Disclosed herein, in certain embodiments, are compositions, solutions, and soft gelatin capsules comprising 17-alpha hydroxyprogesterone caproate (17-HPC). In certain embodiments, also disclosed herein are methods, dosing regimens, and kits for use in the treatment of a disease or condition.
-
公开(公告)号：US10993879B2
公开(公告)日：2021-05-04
申请号：US14860578
申请日：2015-09-21
发明人： Chang Lee , Tao Tom Du
摘要： The present invention relates to a pharmaceutical formulation powder that contains 17α-hydroxyprogesterone caproate (17-OHPC) powder and the method of producing the formulation produces particles that are suitable as an inhalant. The formulations, methods and kits of powdered 17-OHPC as taught herein may be used to reduce cytokine interleukin-17 (IL-17 or IL-17A) levels in both broncheoalveolar lavage fluid (BALF) and blood/serum and involve the inhibition of p38 mitogen activating protein kinase (MAPK) activity. The 17-OHPC powder formulation may be used in a method to treat IL-17 cytokine and/or p38 MAPK mediated auto-immune and auto-inflammatory diseases. Such diseases may include glucocorticoid (GC) insensitive related diseases or conditions. In alternate embodiment, the formulation may include the combined use of budesonide (BUD) and/or fluticasone with 17-OPHC.
-
公开(公告)号：US10987361B2
公开(公告)日：2021-04-27
申请号：US14860680
申请日：2015-09-21
发明人： Tao Tom Du , Chang Lee
IPC分类号： A61K31/573 , A61K9/00 , A61K31/58 , A61K31/57 , A61K31/56
摘要： The present invention relates to the formulations, methods and kits for reducing cytokine interleukin-17 (IL-17 or IL-17A) levels in both broncheoalveolar lavage fluid (BALF) and blood/serum and/or for the inhibition of p38 mitogen activating protein kinase (MAPK) activity involving the use of 17α-hydroxyprogesterone caproate (17-OHPC) or derivatives thereof. The formulation may be in the form of an inhalant containing effective amounts of 17-OHPC, and the formulation may be used in a method to treat IL-17 cytokine and/or p38 MAPK mediated auto-immune and auto-inflammatory diseases. Such diseases may include glucocorticoid (GC) insensitive related diseases or conditions. In alternate embodiment, the formulation may include the combined use of budesonide (BUD) with 17-OPHC.
-
公开(公告)号：US20230020546A1
公开(公告)日：2023-01-19
申请号：US17623331
申请日：2021-03-25
发明人： Tao Tom Du , Xin Du
摘要： The present application provides a use of hydroxyprogesterone caproate for treating multiple diseases that cause a cytokine storm, such as novel coronavirus pneumonia, various virulent virus infections, side effects after monoclonal antibody treatment, side effects after CAR-T treatment, inflammatory bowel disease, and acute pancreatitis. Moreover, the present application also provides a method for treating the diseases by using a corresponding pharmaceutical composition. Experimental results show that progestin hydroxyprogesterone caproate can effectively inhibit the cytokine storm and is expected to be an effective drug for treating diseases such as novel coronavirus pneumonia.
-
公开(公告)号：US20240299415A1
公开(公告)日：2024-09-12
申请号：US18549968
申请日：2021-12-01
发明人： Tao Tom Du , Tao Hu , Xin Du
IPC分类号： A61K31/57 , A61K31/573 , A61P11/00
CPC分类号： A61K31/57 , A61K31/573 , A61P11/00
摘要： A treatment method for interstitial pneumonia by means of hydroxyprogesterone caproate alone or in combination with other drugs, and corresponding pharmaceutical uses, and pharmaceutical compositions. Hydroxyprogesterone caproate can reduce pulmonary inflammation and fibrosis symptoms, reduce pulmonary collagen deposition, and reduce the levels of various inflammatory factors in bronchoalveolar lavage fluid and plasma. Hydroxyprogesterone caproate combined with dexamethasone can improve lipid metabolism abnormalities caused by dexamethasone treatment alone.
-
公开(公告)号：US20230181599A1
公开(公告)日：2023-06-15
申请号：US17923532
申请日：2021-05-06
发明人： Xin Du , Tao Tom Du , Weiwei Hua
CPC分类号： A61K31/57 , A61K45/06 , A61P11/00 , A61K9/4825
摘要： Disclosed herein, in certain embodiments, are compositions, solutions, and soft gelatin capsules comprising 17-alpha hydroxyprogesterone caproate (17-HPC). In certain embodiments, also disclosed herein are methods, dosing regimens, and kits for use in the treatment of a disease or condition.
-
公开(公告)号：US20220193092A1
公开(公告)日：2022-06-23
申请号：US17355957
申请日：2021-06-23
发明人： Tao Hu , Tao Tom Du , Xin Du
摘要： Disclosed is a method and a composition for inhibiting cytokine storm in a subject in need thereof, in particular cytokine release from PBMCs induced by anti-CD28 antibody and/or anti-CD3 antibody, comprising administering progestogen to the subject. The results show that hydroxyprogesterone caproate could inhibit various cytokines release from PBMC induced by anti-CD28 antibody and/or anti-CD3 antibody in a concentration-dependent manner, and could be a potential drug for the treatment of cytokine storm.
-
公开(公告)号：US20210361674A1
公开(公告)日：2021-11-25
申请号：US17240698
申请日：2021-04-26
发明人： Tao Tom DU , Chang LEE
IPC分类号： A61K31/573 , A61K31/58 , A61K9/00 , A61K31/57 , A61K31/56
摘要： The present invention relates to the formulations, methods and kits for reducing cytokine interleukin-17 (IL-17 or IL-17A) levels in both broncheoalveolar lavage fluid (BALF) and blood/serum and/or for the inhibition of p38 mitogen activating protein kinase (MAPK) activity involving the use of 17α-hydroxyprogesterone caproate (17-OHPC) or derivatives thereof. The formulation may be in the form of an inhalant containing effective amounts of 17-OHPC, and the formulation may be used in a method to treat IL-17 cytokine and/or p38 MAPK mediated auto-immune and auto-inflammatory diseases. Such diseases may include glucocorticoid (GC) insensitive related diseases or conditions. In alternate embodiment, the formulation may include the combined use of budesonide (BUD) with 17-OPHC.
-
公开(公告)号：US20240009166A1
公开(公告)日：2024-01-11
申请号：US18254319
申请日：2021-11-24
发明人： Tao Tom DU , Tao HU , XIN DU
IPC分类号： A61K31/351 , A61P9/12 , A61K45/06
CPC分类号： A61K31/351 , A61P9/12 , A61K45/06
摘要： This application provides the use of zanamivir in the preparation of drugs for the treatment or prevention of pre-eclampsia and the corresponding drugs and therapeutic methods; Zanamivir is effective in improving the symptoms of hypertension, proteinuria, elevated creatinine, neuraminidase and sialic acid in pre-eclampsia, increasing NO levels; and improving pregnancy outcomes. The combination of zanamivir and hydroxyprogesterone caproate showed superior results.
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.015 秒)
